First patient enrolled in aclarion's groundbreaking clarity trial

The first clarity patient was enrolled at the texas back institute, a world leader in advancing spine technology, science, and education, as well as patient care clarity is a randomized clinical trial designed to demonstrate nociscan's ability to improve surgical outcomes for chronic low back pain nociscan aims to become the gold standard in identifying sources of low back pain through mr spectroscopy (mrs) and augmented intelligence (ai) company reaffirms internal interim results of clarity expected in q2 2026 broomfield, colo., june 25, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (ai) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the clarity (chronic low back pain randomized independent trial study) trial evaluating nociscan's clinical and economic value in spine surgery.
ACON Ratings Summary
ACON Quant Ranking